A detailed history of Goldman Sachs Group Inc transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,074,200 shares of VKTX stock, worth $74 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,074,200
Previous 642,196 67.27%
Holding current value
$74 Million
Previous $52.7 Million 8.13%
% of portfolio
0.01%
Previous 0.01%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$47.39 - $80.2 $20.5 Million - $34.6 Million
432,004 Added 67.27%
1,074,200 $56.9 Million
Q1 2024

May 15, 2024

SELL
$17.4 - $94.5 $8.31 Million - $45.1 Million
-477,689 Reduced 42.66%
642,196 $52.7 Million
Q4 2023

Feb 13, 2024

BUY
$9.24 - $19.64 $4.85 Million - $10.3 Million
525,296 Added 88.35%
1,119,885 $20.8 Million
Q3 2023

May 14, 2024

SELL
$10.92 - $16.0 $5.74 Million - $8.4 Million
-525,296 Reduced 46.91%
594,589 $6.58 Million
Q3 2023

Nov 14, 2023

SELL
$10.92 - $16.0 $1.07 Million - $1.57 Million
-98,273 Reduced 14.18%
594,589 $6.58 Million
Q2 2023

May 14, 2024

BUY
$14.84 - $24.79 $283,087 - $472,894
19,076 Added 2.83%
692,862 $11.2 Million
Q2 2023

Aug 14, 2023

BUY
$14.84 - $24.79 $283,087 - $472,894
19,076 Added 2.83%
692,862 $11.2 Million
Q1 2023

May 14, 2024

BUY
$8.08 - $17.33 $4.8 Million - $10.3 Million
594,066 Added 745.19%
673,786 $11.2 Million
Q1 2023

May 11, 2023

BUY
$8.08 - $17.33 $4.8 Million - $10.3 Million
594,066 Added 745.19%
673,786 $11.2 Million
Q4 2022

May 14, 2024

BUY
$2.72 - $9.4 $116,103 - $401,239
42,685 Added 115.26%
79,720 $749,000
Q4 2022

Feb 13, 2023

BUY
$2.72 - $9.4 $116,103 - $401,239
42,685 Added 115.26%
79,720 $749,000
Q3 2022

May 14, 2024

SELL
$2.55 - $3.89 $51,821 - $79,052
-20,322 Reduced 35.43%
37,035 $101,000
Q3 2022

Nov 10, 2022

SELL
$2.55 - $3.89 $51,821 - $79,052
-20,322 Reduced 35.43%
37,035 $100,000
Q2 2022

May 14, 2024

SELL
$2.11 - $3.15 $2.24 Million - $3.35 Million
-1,062,528 Reduced 94.88%
57,357 $166,000
Q2 2022

Aug 15, 2022

SELL
$2.11 - $3.15 $428,313 - $639,424
-202,992 Reduced 77.97%
57,357 $166,000
Q1 2022

May 16, 2022

BUY
$3.0 - $4.88 $520,056 - $845,957
173,352 Added 199.26%
260,349 $781,000
Q4 2021

Feb 14, 2022

SELL
$4.6 - $6.72 $246,624 - $360,286
-53,614 Reduced 38.13%
86,997 $400,000
Q3 2021

Nov 10, 2021

BUY
$5.58 - $7.04 $784,609 - $989,901
140,611 New
140,611 $883,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $5.28B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.